Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Adherence to long-term therapies in cystic fibrosis: a French cross-sectional study linking prescribing, dispensing, and hospitalization data.
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 4631780
Author(s) Rouzé, Héloïse; Viprey, Marie; Allemann, Samuel; Dima, Alexandra L; Caillet, Pascal; Denis, Angélique; Poupon-Bourdy, Stéphanie; Camara, Boubou; Llerena, Catherine; Reix, Philippe; Durieu, Isabelle; Reynaud, Quitterie; Touzet, Sandrine
Author(s) at UniBasel Allemann, Samuel
Year 2019
Title Adherence to long-term therapies in cystic fibrosis: a French cross-sectional study linking prescribing, dispensing, and hospitalization data.
Journal Patient preference and adherence
Volume 13
Pages / Article-Number 1497-1510
Keywords administrative claims data; chronic treatment; cystic fibrosis; medication adherence; prescription data
Abstract

Cystic fibrosis (CF) is a life-shortening genetic condition that usually affects several organs and involves significant treatment burden. Adherence to medication is important for successful CF management.; To describe medication adherence according to age, therapeutic class, and pharmaceutical form in adults and children followed in four regional CF centers in France.; We conducted a cross-sectional study with non-transplanted patients followed in two adult and two pediatric centers during 2015 who were covered by the French National Health Insurance (NHI). Sociodemographic, clinical, hospitalization, and prescription data were collected from patient medical records. Medication dispensations were extracted from the regional French NHI database. Adherence was calculated over 12 months using continuous medication availability (CMA) accounting for dose adjustments and hospitalizations. Drug-specific CMA was computed in R with the AdhereR package for each medication prescribed more than 3 months, which was averaged to obtain a composite CMA score (cCMA) for all treatments and per therapeutic class as well as pharmaceutical form for each patient.; A total of 228 patients were included. The number of chronic medications increased with age (; r; =0.50,; p; <0.001): a median of 7 medications per patient were prescribed. The mean±SD cCMA was significantly different between age groups (; p; =0.0098): it was 0.71±0.20 for the 0-5 years age group, 0.73±0.16 for 6-11 years, 0.64±0.17 for 12-17 years, 0.57±0.23 for 18-25 years, and 0.65±0.20 for the over 25 years age group. cCMA varied significantly according to pharmaceutical forms: the mean±SD cCMA was 0.70±0.21 for oral medications and 0.54±0.28 for inhaled medications (; p; <0.001).; This study suggests that adherence to medication regimens in CF patients remains suboptimal and varies substantially between age groups and pharmaceutical forms. These variations in adherence should be considered when developing effective strategies to improve adherence.

ISSN/ISBN 1177-889X
Full Text on edoc
Digital Object Identifier DOI 10.2147/PPA.S211769
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/31564837
   

MCSS v5.8 PRO. 0.328 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
08/05/2024